Analysts Anticipate Endo International PLC (ENDP) Will Announce Quarterly Sales of $696.72 Million

Equities analysts expect that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will report sales of $696.72 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Endo International’s earnings, with estimates ranging from $672.80 million to $713.63 million. Endo International posted sales of $714.70 million in the same quarter last year, which suggests a negative year-over-year growth rate of 2.5%. The company is expected to announce its next earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Endo International will report full-year sales of $2.87 billion for the current fiscal year, with estimates ranging from $2.83 billion to $2.89 billion. For the next year, analysts expect that the business will report sales of $2.88 billion, with estimates ranging from $2.63 billion to $3.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.11. The company had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $0.67 earnings per share.

A number of equities analysts recently weighed in on ENDP shares. ValuEngine upgraded Endo International from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Zacks Investment Research downgraded Endo International from a “hold” rating to a “sell” rating in a research note on Thursday, February 7th. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Endo International in a research note on Friday, March 1st. Leerink Swann downgraded Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Finally, Svb Leerink downgraded Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company’s stock. Endo International has a consensus rating of “Hold” and an average target price of $14.88.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENDP. Oregon Public Employees Retirement Fund raised its position in Endo International by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock valued at $621,000 after purchasing an additional 1,397 shares during the last quarter. Piedmont Investment Advisors Inc. grew its stake in Endo International by 3.5% in the fourth quarter. Piedmont Investment Advisors Inc. now owns 47,942 shares of the company’s stock valued at $350,000 after acquiring an additional 1,607 shares during the period. Mason Street Advisors LLC grew its stake in Endo International by 3.4% in the first quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock valued at $515,000 after acquiring an additional 2,134 shares during the period. Neuburgh Advisers LLC grew its stake in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after acquiring an additional 3,036 shares during the period. Finally, Comerica Bank grew its stake in Endo International by 2.1% in the first quarter. Comerica Bank now owns 198,605 shares of the company’s stock valued at $1,650,000 after acquiring an additional 4,001 shares during the period. 90.95% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ ENDP traded down $0.15 on Friday, reaching $5.97. The company had a trading volume of 29,817 shares, compared to its average volume of 3,280,272. The stock has a market cap of $1.45 billion, a PE ratio of 2.07 and a beta of 1.12. Endo International has a 1 year low of $5.96 and a 1 year high of $18.50.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Read More: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.